Comgest Global Investors S.A.S. Has $6.05 Million Stake in Stevanato Group S.p.A. (NYSE:STVN)

Comgest Global Investors S.A.S. trimmed its position in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 27.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 277,820 shares of the company's stock after selling 106,010 shares during the period. Comgest Global Investors S.A.S. owned approximately 0.09% of Stevanato Group worth $6,054,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of STVN. M&T Bank Corp bought a new stake in shares of Stevanato Group in the 4th quarter worth about $572,000. Mutual of America Capital Management LLC acquired a new stake in Stevanato Group during the 4th quarter worth $13,848,000. Advantage Alpha Capital Partners LP lifted its stake in shares of Stevanato Group by 27.3% in the 4th quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company's stock valued at $6,403,000 after purchasing an additional 63,041 shares during the period. Allianz SE bought a new position in shares of Stevanato Group in the 4th quarter worth $748,000. Finally, Zions Bancorporation N.A. grew its stake in shares of Stevanato Group by 29.7% during the fourth quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock worth $1,482,000 after purchasing an additional 15,555 shares during the period.

Stevanato Group Stock Down 0.9 %

STVN traded down €0.20 ($0.23) during trading on Friday, reaching €21.88 ($24.93). The company had a trading volume of 349,200 shares, compared to its average volume of 353,229. The business's fifty day moving average price is €20.56 and its 200 day moving average price is €20.67. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a 12 month low of €16.56 ($18.87) and a 12 month high of €29.11 ($33.17). The company has a market cap of $6.63 billion, a P/E ratio of 46.55, a PEG ratio of 7.18 and a beta of 0.52.

Stevanato Group (NYSE:STVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.23). The company had revenue of €352.68 million for the quarter, compared to analyst estimates of €346.26 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. Equities analysts anticipate that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on STVN. UBS Group reduced their target price on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. William Blair restated an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Stevanato Group currently has a consensus rating of "Moderate Buy" and a consensus price target of €25.70 ($29.29).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.